Supplementary protection certificate meaning

In this issue: Probate Court of Protection UK taxes for Private Client HMRC Manuals updates Tax avoidance, evasion and non-compliance Insolvency—Private Client Digital assets and cryptoassets Charity and philanthropy Contentious trusts and estates Pensions, insurance and tax efficient investments International Question of the week Additional Private Client updates this week Daily and weekly news alerts LexTalk®Private Client: a Lexis®PSL community New and updated content Dates for your diary Trackers Latest Q&As Useful information Probate HMCTS probate enquiry line—temporary reduced hours From 14 February 2024, and for 12 weeks, the HMCTS probate helpline will run on reduced hours: 9am to 1pm, Monday to Friday. The HMCTS Probate Service remains available via web‑chat from 9am to 5pm, Monday to Friday. Source: HMCTS Probate LinkedIn post. MoJ urges those entitled to claim dormant funds held by CFO to act now The Ministry of Justice...

In this issue Patents Copyright & associated rights Daily and weekly news alerts New and updated content Dates for your diary Trackers Useful information Patents Article 3(d) entitlement of an uncombined medicinal product (drospirenone) to an SPC (Laboratorios Leon Farma SA v Comptroller) The court was asked, at its core, whether the earlier Court of Justice ruling in Medeva BV v Comptroller General of Patents, Designs and Trade Marks, Case C-322/10, operates to block the award of a supplementary protection certificate (SPC) to a product where a prior approval existed only as part of a combination therapy. The court answered in the affirmative and held that the Intellectual Property Office (IPO) was right to decline an SPC for drospirenone by applying Medeva. Because there was an earlier marketing authorisation (MA) for drospirenone used together with oestrogen, the subsequent MA for drospirenone as a standalone active could not be regarded as the first MA for drospirenone. Written...

In this issue: Intellectual property Research and development Pharmaceuticals—regulatory framework Competition in life sciences LexTalk®Life Sciences: a Lexis®Nexis community Daily and weekly news alerts New and updated content Dates for your diary Trackers Useful information Intellectual property EPO registers more than 27,000 patents in the Unitary Patent system The European Patent Office (EPO) reports registering over 27,000 unitary patents in the Unitary Patent’s inaugural year, following its launch in June 2023. This means nearly one in four (23%) granted European patents now cover all participating Member States, with the share continuing to rise. The newly established Unified Patent Court (UPC) has handled around 350 matters to date and also provides a single forum for disputes concerning both unitary patents and non‑unitary European patents. In addition, the European Commission plans a unitary supplementary protection certificate to permit the extension of unitary patent protection for certain authorised pharmaceutical and plant protection products on a unitary...

A–B | C–D | E–H | I–N | O–P. Qualified person (QP) The qualified person (QP) must confirm that every batch of medicinal products is manufactured and checked in line with UK or EU Member State law and in keeping with the marketing authorisation (MA) terms. See also: batch release marketing authorisation (MA) medicinal product Practice Note: Manufacturing of medicinal products for human use Qualified person for pharmacovigilance (QPPV) A qualified person for pharmacovigilance (QPPV) is the individual who, by law, holds personal responsibility for the safety of a human medicinal product. See also: adverse reaction marketing authorisation (MA) medicinal product Practice Note: Pharmacovigilance Rare disease See: orphan medicinal product (OMP)...

ARCHIVED This Practice Note is archived and no longer maintained. It monitored EU cases pertinent to the life sciences sector during 2020–2022. To follow EU case progress from 2023 onwards, including live matters, see Practice Note: Life sciences cases tracker—EU. For current EU legislative proposals, consultations and developments relevant to life sciences, see Practice Note: Life sciences tracker—EU. For current UK legislative proposals, consultations and developments, as well as notable UK cases relevant to life sciences, see Practice Notes: Life sciences tracker—UK and Life sciences cases tracker—UK... Judgments—Supplementary protection certificates For archived supplementary protection certificate (SPC) rulings, see Practice Note: Life sciences tracker [Archived]—Judgments—Supplementary protection certificates... Court of Justice of the European Union Santen SAS v Directeur général de l’Institut national de la propriété industrielle (Case C-673/18, ECLI:EU:C:2020:531) — judgment delivered on 9 July 2020...

This Practice Note is designed to monitor the progress of EU cases relevant to the life sciences industry. For earlier life sciences materials, see Practice Note: Life sciences tracker [Archived]... Judgments-Supplementary protection certificates For archived supplementary protection certificate (SPC) judgments, see Practice Note: Life sciences tracker [Archived]-Judgments-Supplementary protection certificates... Court of Justice of the European Union What's happening? When? Find out more Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC; Merck Sharp & Dohme LLC v Clonmel Healthcare Limited - Joined Cases C-119/22 and C-149/22 19 December 2024: preliminary ruling of the Court of Justice (Third Chamber) issued. 6 June 2024: Opinion of the Advocate General (AG). 21 February 2022: reference made to the Court of Justice by the Supreme Court of Ireland. 17 February 2022: reference made to the Court of Justice by the Supreme Court of Finland. Requirements for obtaining an...